» Articles » PMID: 33178673

Process Characterization by Definitive Screening Design Approach on DNA Vaccine Production

Overview
Date 2020 Nov 12
PMID 33178673
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Plasmid DNA is a vital biological tool for molecular cloning and transgene expression of recombinant proteins; however, decades ago, it has become an exceptionally appealing as a potential biopharmaceutical product as genetic immunization for animal and human use. The demand for large-quantity production of DNA vaccines also increases. Thus, we, herein, presented a systematic approach for process characterization of fed-batch DH5α fermentation producing a porcine DNA vaccine. Design of Experiments (DoE) was employed to determine process parameters that have impacts on a critical quality attribute of the product, which is the active form of plasmid DNA referred as supercoiled plasmid DNA content, as well as the performance attributes, which are volumetric yield and specific yield from fermentation. The parameters of interest were temperature, pH, dissolved oxygen, cultivation time, and feed rate. Using the definitive-screening design, there were 16 runs, including 3 additional center points to create the predictive model, which then was used to simulate the operational ranges for capability analysis.

Citing Articles

Lifecycle DoE-The Companion for a Holistic Development Process.

Kunzelmann M, Wittmann A, Presser B, Brosig P, Marhoffer P, Haider M Bioengineering (Basel). 2024; 11(11).

PMID: 39593749 PMC: 11591819. DOI: 10.3390/bioengineering11111089.


Optimization of an Ultra-Sonication Extraction Method for Major Compounds Found in Using Design of Experiment.

Chokwe R, Dube S, Nindi M Molecules. 2022; 27(9).

PMID: 35566186 PMC: 9099649. DOI: 10.3390/molecules27092836.


Toward QbD Process Understanding on DNA Vaccine Purification Using Design of Experiment.

Hocharoen L, Noppiboon S, Kitsubun P Front Bioeng Biotechnol. 2021; 9:657201.

PMID: 34055759 PMC: 8153680. DOI: 10.3389/fbioe.2021.657201.

References
1.
Dangoor A, Lorigan P, Keilholz U, Schadendorf D, Harris A, Ottensmeier C . Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine. Cancer Immunol Immunother. 2010; 59(6):863-73. PMC: 11030722. DOI: 10.1007/s00262-009-0811-7. View

2.
Ingolotti M, Kawalekar O, Shedlock D, Muthumani K, Weiner D . DNA vaccines for targeting bacterial infections. Expert Rev Vaccines. 2010; 9(7):747-63. PMC: 2962930. DOI: 10.1586/erv.10.57. View

3.
Wang X, Germansderfer A, Harms J, Rathore A . Using statistical analysis for setting process validation acceptance criteria for biotech products. Biotechnol Prog. 2007; 23(1):55-60. DOI: 10.1021/bp060359c. View

4.
Abu-Absi S, Yang L, Thompson P, Jiang C, Kandula S, Schilling B . Defining process design space for monoclonal antibody cell culture. Biotechnol Bioeng. 2010; 106(6):894-905. DOI: 10.1002/bit.22764. View

5.
Urthaler J, Buchinger W, Necina R . Improved downstream process for the production of plasmid DNA for gene therapy. Acta Biochim Pol. 2005; 52(3):703-11. View